Interestingly, recent studies also found that patients with different cancer types that harboring SETD2 deleterious mutations showed improved response to ICB therapy.57,58 Collectively, these findings firstly demonstrated the mechanisms of SETD2_Y1666C mutation in modulating immune surveillance and further supported the notion that the mutation is relevant to a better response to ICB treatment in clinical trials. The gene discussed is SETD2; the disease is cancer.